Abstract

The various adjuvant treatments to be proposed for endometrial cancers, alone or in combination are external beam radiotherapy (EBRT), vaginal brachytherapy (VBT), chemotherapy, targeted therapies and/or immunotherapy. In our systematic review, we will attempt to detail the various therapeutic indications, taking into account the latest technical advances and the inclusion of molecular factors in the new classification. Endometrial cancer is very common gynecological tumor in developed countries, due to increasing life expectancy. Generally discovered at the localized stage (70%), the standard treatment remains surgery, including total hysterectomy with bilateral salpingo oophorectomy and lymph node dissection or sentinel biopsy of pelvic +/- para-aortic nodes. The choice of adjuvant treatment depends essentially on clinico-pathological risk factors. Recently, a new molecular classification has identified 4 subgroups with different prognoses to be taken into account when choosing adjuvant treatments. The various treatments to be proposed alone or in combination are external beam radiotherapy (EBRT), vaginal brachytherapy (VBT), chemotherapy, targeted therapies and/or immunotherapy. In our systematic review, we will attempt to detail the various therapeutic indications, taking into account the latest technical advances and the inclusion of molecular factors in the new classification.

Keywords

endometrial cancer, adjuvant treatment, chemotherapy, radiotherapy, molecular profile